After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... Seaport said the money would support a pipeline of improved neuropsychiatric drug ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating on January 8.Stay Ahead of the ...

Seaport Therapeutics (“Seaport” or the “Company ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is ...